Maximal Resection of Glioblastomas May Up Survival
Maximal resection of contrast-enhanced tumor linked to increased overall survival across all subgroups.
Maximal resection of contrast-enhanced tumor linked to increased overall survival across all subgroups.
Repeat biopsies may be needed prior to patient inclusion in targeted-therapy trials.
A phase 0 study of ribociclib in patients with recurrent glioblastoma seeks to inform the feasibility of the use of CDK 4/6 inhibitors for deadly brain tumors.
Four distinct immunologic groups independent of patient age were identified and correlated with overall survival in patients with high-grade glioma.
Survivors of childhood low-grade gliomas treated with radiotherapy have poorer neuropsychological and socioeconomic-status (SES) outcomes.
Improvements to PFS and “clinically meaningful reductions in daily corticosteroid use” were said to be linked to the addition of bevacizumab in glioblastoma.
Computer-assisted diagnosis (CAD) can help physicians detect growth of low-grade gliomas.
AbbVie has halted enrollment in all ongoing studies of depatuxizumab mafodotin, after an Independent Data Monitoring Committee (IDMC) recommended a phase 3 study of the treatment be stopped due to a lack of survival benefit.
This study involved the engineering of CAR-T cells specific for the EGFRvIII antigen to also secrete bispecific T cell engagers (BiTEs) against wild-type EGFR.
The researchers speculated that the delivery of alternating electric fields to GBM cells may facilitate the delivery of chemotherapy.